MXPA06011890A - Derivados de pirimidina para tratar el crecimiento celular anomalo. - Google Patents

Derivados de pirimidina para tratar el crecimiento celular anomalo.

Info

Publication number
MXPA06011890A
MXPA06011890A MXPA06011890A MXPA06011890A MXPA06011890A MX PA06011890 A MXPA06011890 A MX PA06011890A MX PA06011890 A MXPA06011890 A MX PA06011890A MX PA06011890 A MXPA06011890 A MX PA06011890A MX PA06011890 A MXPA06011890 A MX PA06011890A
Authority
MX
Mexico
Prior art keywords
ylamino
methyl
alkyl
dihydro
trifluoromethyl
Prior art date
Application number
MXPA06011890A
Other languages
English (en)
Spanish (es)
Inventor
Michael Joseph Luzzio
John Charles Kath
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA06011890(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA06011890A publication Critical patent/MXPA06011890A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
MXPA06011890A 2004-05-14 2005-05-02 Derivados de pirimidina para tratar el crecimiento celular anomalo. MXPA06011890A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14
PCT/IB2005/001201 WO2005111023A1 (en) 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth

Publications (1)

Publication Number Publication Date
MXPA06011890A true MXPA06011890A (es) 2006-12-14

Family

ID=34966230

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06011890A MXPA06011890A (es) 2004-05-14 2005-05-02 Derivados de pirimidina para tratar el crecimiento celular anomalo.

Country Status (27)

Country Link
EP (1) EP1751143A1 (zh)
JP (1) JP4099212B2 (zh)
KR (1) KR100886990B1 (zh)
CN (2) CN102127058A (zh)
AP (1) AP2241A (zh)
AR (1) AR049097A1 (zh)
AU (2) AU2005243397A1 (zh)
BR (1) BRPI0511138A (zh)
CA (1) CA2566707A1 (zh)
CR (1) CR8749A (zh)
EA (1) EA200601796A1 (zh)
EC (1) ECSP066997A (zh)
GE (1) GEP20104875B (zh)
GT (1) GT200500113A (zh)
IL (1) IL178828A0 (zh)
MA (1) MA28583B1 (zh)
MX (1) MXPA06011890A (zh)
NL (2) NL1029045C2 (zh)
NO (1) NO20064576L (zh)
NZ (1) NZ550448A (zh)
PA (1) PA8632601A1 (zh)
PE (1) PE20060240A1 (zh)
TN (1) TNSN06370A1 (zh)
TW (1) TWI303635B (zh)
UY (1) UY28894A1 (zh)
WO (1) WO2005111023A1 (zh)
ZA (1) ZA200608394B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1763514A2 (en) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
EP1966207A2 (en) * 2005-12-21 2008-09-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
DK2146779T3 (en) * 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
EP2183225A1 (en) * 2007-07-17 2010-05-12 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
US8461147B2 (en) * 2007-12-03 2013-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
KR101956261B1 (ko) * 2008-05-21 2019-03-08 어리어드 파마슈티칼스, 인코포레이티드 키나아제 억제제로서 포스포러스 유도체
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2014174745A1 (ja) * 2013-04-26 2014-10-30 国立大学法人京都大学 Ｅｇ５阻害剤
CN109608444B (zh) * 2018-11-27 2022-02-11 中国药科大学 含异吲哚啉酮的erk抑制剂及其制备方法与用途
CN111732548B (zh) * 2020-06-11 2022-06-17 浙江大学 N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
DK1625121T3 (da) * 2002-12-20 2010-05-10 Pfizer Prod Inc Pyrimidinderivater til behandling af abnorm cellevækst
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
IL178828A0 (en) 2007-03-08
NL1031845A1 (nl) 2006-07-31
AP2006003790A0 (en) 2006-10-31
JP2007537234A (ja) 2007-12-20
AU2009238255A1 (en) 2009-12-03
PA8632601A1 (es) 2006-06-02
TNSN06370A1 (fr) 2008-02-22
AR049097A1 (es) 2006-06-28
PE20060240A1 (es) 2006-04-01
NL1029045C2 (nl) 2006-06-02
NL1031845C2 (nl) 2006-11-23
GT200500113A (es) 2006-01-10
CN102127058A (zh) 2011-07-20
GEP20104875B (en) 2010-01-11
BRPI0511138A (pt) 2007-11-27
NO20064576L (no) 2006-11-07
AP2241A (en) 2011-06-01
TWI303635B (en) 2008-12-01
EP1751143A1 (en) 2007-02-14
CA2566707A1 (en) 2005-11-24
MA28583B1 (fr) 2007-05-02
JP4099212B2 (ja) 2008-06-11
ECSP066997A (es) 2007-02-28
KR100886990B1 (ko) 2009-03-04
KR20070012477A (ko) 2007-01-25
AU2005243397A1 (en) 2005-11-24
CN1953974A (zh) 2007-04-25
ZA200608394B (en) 2008-05-28
NZ550448A (en) 2010-11-26
CR8749A (es) 2006-12-05
TW200539871A (en) 2005-12-16
NL1029045A1 (nl) 2005-11-15
WO2005111023A1 (en) 2005-11-24
EA200601796A1 (ru) 2007-04-27
UY28894A1 (es) 2005-12-30

Similar Documents

Publication Publication Date Title
US7109337B2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
US7145008B2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
JP4099212B2 (ja) 異常な細胞増殖を処置するためのピリミジン誘導体
US7208499B2 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
EP1625121B1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
NL2000375C2 (nl) Pyrimidinederivaten voor de behandeling van abnormale celgroei.
MXPA06013165A (es) Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
US20060205945A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth